TUSC2 and atrial fibrillation: The same group also proved that the antitumour activity of a combination of TUSC2 gene (tumor suppressor candidate 2) delivered by nanovesicles and erlotinib (epidermal growth factor receptor [EGFR] inhibitor) was enhanced by AF both in vitro and in vivo.94